A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema

Tomoo Kishaba,1 Yousuke Shimaoka,2 Hajime Fukuyama,1 Kyoko Yoshida,3 Maki Tanaka,4 Shin Yamashiro,1 Hitoshi Tamaki5

ABSTRACT

Objectives: Our purpose was to assess the clinical data, predictors of mortality and acute exacerbation (AE) in combined pulmonary fibrosis and emphysema (CPFE) patients.

Design: Single-centre retrospective cohort study.

Setting: Teaching hospital in Japan.

Participants: We identified 93 CPFE patients with high-resolution computed tomographic (HRCT) through multidisciplinary discussion. Patients who had connective tissue disease, drug-associated interstitial lung disease and occupationally related interstitial lung disease, such as asbestosis and silicosis, were excluded.

Interventions: There were no interventions.

Methods: Medical records and HRCT scans from January 2002 through December 2007 were reviewed retrospectively at our hospital. Ninety-three patients had CPFE.

Results: The mean age of CPFE patients was 74 years. Idiopathic pulmonary fibrosis and non-specific interstitial pneumonia were observed as distinct HRCT patterns. Forty-two patients showed finger clubbing. Mean serum Krebs von den Lungen-6 (KL-6) and per cent predicted forced vital capacity (%FVC) were 1089 IU/l, 63.86%, respectively. Twenty-two patients developed AE during observation period. Baseline KL-6 was a strong predictor of AE (OR = 1.0016, p = 0.009). Finger clubbing (HR = 2.2620, p = 0.015) and per cent predicted forced expiratory volume in one second/%FVC more than 1.2 were independent predictors of mortality in CPFE.

Conclusions: Baseline serum KL-6 was a useful predictor of AE (cut-off = 1050, receiver operator characteristic curve: 0.7720), which occurred in 24% (22/93) of the CPFE patients. Finger clubbing and per cent predicted forced expiratory volume in one second/%FVC more than 1.2 were independent predictors of mortality.

Emphysema is sometimes recognized in the setting of idiopathic pulmonary fibrosis (IPF) and usually occurs with elevated lung volume, and patients with both emphysema and fibrosis (CPFE) usually have elevated lung volumes compared with patients with IPF alone. In CPFE, lung volume is preserved in many patients, even in those at advanced stages, because supervening fibrosis offsets the effect of emphysema. CPFE patients also more often have pulmonary arterial hypertension (PAH). PAH has been shown to be a significant prognostic indicator for
Mortality predictors in CPFE

both IPF and chronic obstructive pulmonary disease. In patients with lung cancer, CPFE is more prevalent than fibrosis. Recently, CPFE syndrome has been individualised, partly on the basis of distinct characteristics observed by high-resolution computed tomography (HRCT) of the chest.

There is very little information on predictors of mortality for CPFE. Patients with CPFE often have severe dyspnoea and poor cardiopulmonary reserve, and many patients cannot tolerate invasive procedures such as video-assisted thoracoscopic surgery.

Thus, the objective of the present study was to determine the predictors of acute exacerbation (AE) and mortality in CPFE patients using non-invasive methods.

METHODS

Study population and HRCT assessment

We retrospectively investigated our medical records and HRCT scans from Okinawa Chubu Hospital, Okinawa, Japan, from 1 January 2002 through 31 December 2007. During this period, we had 319 interstitial lung disease (ILD) patients. Eligible patients were men and women aged 18 years or older with a proven diagnosis of IPF or non-specific interstitial pneumonia (NSIP) according to the American Thoracic Society/European Respiratory Society (ATS/ERS) statement. Among all ILD patients, we identified 93 CPFE patients through multidisciplinary discussion including our pulmonologists and radiologists. We excluded patients if (1) they were without HRCT imaging, (2) had connective tissue disease, (3) had drug-associated ILD and (4) had occupational-related ILD, such as asbestosis and silicosis. Demographic and clinical data were obtained, including age, gender, smoking history, dyspnoea duration, comorbidity, clubbing, Krebs von den Lungen-6 (KL-6) levels and ultrasound cardiography findings. In terms of PAH, we estimated with ultrasound cardiography. We also checked physiological data including forced expiratory volume in one second (FEV₁), per cent predicted forced vital capacity volume in one second (%FEV₁), forced vital capacity (FVC) and per cent predicted forced vital capacity (%FVC). We only included pulmonary function data determined within 6 months of the date of HRCT.

The HRCT scan imaging patterns were evaluated according to the ATS/ERS criteria. We diagnosed IPF patients using the new ATS/ERS and Japanese Respiratory Society/Latin America Thoracic Association criteria. Patients who met the following criteria, as described by Cottin et al., were diagnosed as having CPFE: (1) the presence of emphysema on CT, defined as well-demarcated areas of decreased attenuation compared with contiguous normal lung, marginated by a very thin (<1 mm) wall or no wall and/or multiple bullae (>1 cm) with upper zone predominance, and (2) the presence of significant pulmonary fibrosis on CT, defined as reticular opacities with peripheral and basal predominance, with or without traction bronchiectasis that occurs with or without honeycombing. Regarding AE, we defined by the following criteria: (1) sudden deterioration of dyspnoea within 30 days, (2) new bilateral infiltration on chest radiograph and (3) pulmonary infection or other known causes were excluded by bronchoalveolar lavage. Survival time was defined from the date of HRCT to death or last observation date. The Ethics Committee of Okinawa Chubu Hospital approved this study protocol.

Statistical methods

Clinical data are presented as means±SDs or medians (range), depending on distribution. Group comparisons were made using unpaired t tests, the Wilcoxon rank sum test, χ² statistics and Fisher’s exact test, as appropriate. Logistic regression analysis was performed to determine the relationship between clinical parameters and AE. A Cox proportional hazards model analysis was performed to determine the relationships between clinical parameters, physiological indices, HRCT imaging patterns and survival. Clinical data analyses were performed using STATA software V.11.0 (Stata Corp). Statistical significance was defined as a p value <0.05.

RESULTS

Patient characteristics, AE and clinical parameters

The flow diagram in figure 1 shows how the patients were identified. Ninety-three CPFE patients (76 men, 17 women) were identified between 2002 and 2007. The mean age was 73 years, and 82% of the patients were men. The mean time from symptoms to diagnosis was 12.68 months (0–96 months). The mean follow-up period was 30.7 months (0–74.6 months). All patients had histories of smoking (mean: 62 pack-years). The mean modified Medical Research Council (mMRC) breathlessness score was 2.5. Bibasilar fine crackles were auscultated in all patients and 42 (45%) had finger clubbing. The baseline %FEV₁ (FEV₁/average %FEV₁ for similar age, sex and body composition) was 70.95%, and the baseline per cent predicted FVC was 63.86%. During observation period, 67 patients (72%) died. The clinical characteristics of both survivors and non-survivors are summarised in table 1.

The mean partial pressures of oxygen (PaO₂) and carbon dioxide (PaCO₂) were 63 and 43 mm Hg, respectively. Thirty-two patients (34%) received home oxygen therapy and 36 (39%) had PAH. The mean systolic pulmonary arterial pressure was 62 mm Hg. CPFE patients frequently have been reported to have lung cancer, especially squamous cell carcinoma. However, in our cohort, only 12 (13%) patients developed lung cancer.

Among the 93 patients, 22 (24%) developed AE, which met the ATS/ERS criteria. We performed univariate analysis to determine predictors of AE. Age, mMRC score, CT pattern and baseline serum KL-6 were identified as possible predictors of AE. Logistic regression analysis was performed for these four factors, baseline
serum KL-6 was found to be the strongest predictor of AE in the CPFE patients (OR = 1.0016, p = 0.009) (table 2). Using receiver operator characteristic curve (ROC) analysis, the useful KL-6 threshold was determined to be 1050 (ROC: 0.7720).

**HRCT imaging and predictors of mortality**

According to the ATS/ERS criteria, the patients were divided into those with usual interstitial pneumonia (UIP) patterns and those with NSIP patterns. There were 68 patients in the IPF-pattern group and 25 patients in the NSIP-pattern group. The HRCT images also showed patterns indicating that 51 patients had paraseptal emphysema, 28 had centrilobular emphysema and 14 had panlobular emphysema. Detailed results are presented in (table 3).

The mean survival of CPFE patients was 30.7 months (0.10–75.63 months) (figure 2). Patients with finger clubbing or increased ratio of %FEV\textsubscript{1} to %FVC showed poor survival in CPFE patients (figures 3 and 4). Regarding ratio of %FEV\textsubscript{1} to %FVC, we chose 1.2 which was most useful threshold for predictor of mortality using ROC analysis (ROC: 0.7671). Initially, we performed univariate analysis with a cut-off value of 0.1, which showed that baseline KL-6, finger clubbing, PaO\textsubscript{2} and %FEV\textsubscript{1}/%FVC > 1.2 were independent predictors of mortality. Cox proportional hazards regression analysis showed that finger clubbing (HR = 2.2620, p = 0.015) and ratio of %FEV\textsubscript{1} to %FVC more than 1.2 (HR = 1.9259, p = 0.048) were the strongest independent predictors of mortality in CPFE patients at our hospital (table 4).

**DISCUSSION**

Previous studies have reported a high prevalence of PAH and lung cancer in CPFE patients. These comorbidities were associated with poor prognosis; the 1-year survival rate for CPFE patients with PAH was only 60%. Among these patients, high mean pulmonary arterial pressure, high pulmonary vascular resistance, high heart rate and low diffusing capacity for carbon monoxide (DL\textsubscript{co}) were significantly associated with poor outcome. In one study, CPFE patients had a fivefold higher mortality risk (adjusted HR 5.10, 95% CI 1.75 to 14.9) in non-malignant situations. In the present study, only 12

**Table 1** Patient clinical characteristics in CPFE

<table>
<thead>
<tr>
<th></th>
<th>Survivors (n=26)</th>
<th>Non-survivors (n=67)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, year (mean)</td>
<td>73.19±1.18 (57–84)</td>
<td>73.83±7.07 (56–91)</td>
<td>0.5815</td>
</tr>
<tr>
<td>Male sex, %</td>
<td>85</td>
<td>81</td>
<td>0.6570</td>
</tr>
<tr>
<td>Pack-year</td>
<td>60±22.0 (5–110)</td>
<td>64±31.4 (0–180)</td>
<td>0.5754</td>
</tr>
<tr>
<td>mMRC scale</td>
<td>2.6±0.88 (1–4)</td>
<td>2.5±0.93 (1–4)</td>
<td>0.5991</td>
</tr>
<tr>
<td>Dyspnoea duration, months</td>
<td>11.04±5.73 (0–18)</td>
<td>13.07±14.20 (0–96)</td>
<td>0.4821</td>
</tr>
<tr>
<td>Clubbing, %</td>
<td>12</td>
<td>55</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>KL-6, IU/I</td>
<td>852±278 (505–1200)</td>
<td>1174±725 (201–4250)</td>
<td>0.0413</td>
</tr>
<tr>
<td>Systolic PAP, mm Hg</td>
<td>45</td>
<td>75</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Baseline FEV\textsubscript{1}, %</td>
<td>71.14±8.72 (59.6–103.9)</td>
<td>70.88±9.25 (31.4–106.3)</td>
<td>0.9128</td>
</tr>
<tr>
<td>Baseline FVC, %</td>
<td>68.52±9.09 (57–99.7)</td>
<td>61.89±9.48 (24.9–82.3)</td>
<td>0.0058</td>
</tr>
<tr>
<td>HOT, %</td>
<td>12</td>
<td>43</td>
<td>0.0035</td>
</tr>
<tr>
<td>Paraseptal emphysema, %</td>
<td>19</td>
<td>69</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Acute exacerbation, n (%)</td>
<td>0 (0)</td>
<td>22 (32)</td>
<td>0.0007</td>
</tr>
<tr>
<td>%FEV\textsubscript{1}/%FVC &gt; 1.2, %</td>
<td>19</td>
<td>79</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cancer, %</td>
<td>0</td>
<td>18</td>
<td>0.1068</td>
</tr>
<tr>
<td>Cardiovascular, %</td>
<td>27</td>
<td>40</td>
<td>0.2339</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>58.2±3.90</td>
<td>56.9±5.19</td>
<td>0.2337</td>
</tr>
<tr>
<td>Survival time, months</td>
<td>50.16±17.79 (26–96)</td>
<td>25.68±21.54 (1–98)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD and mean %predicted ± SD.

CPFE, combined pulmonary fibrosis and emphysema; FEV\textsubscript{1}, forced expired volume in one second; %FEV\textsubscript{1}, per cent predicted forced expired volume in one second; FVC, forced vital capacity; HOT, Home Oxygen Therapy; IPF, idiopathic pulmonary fibrosis; mMRC, modified Medical Research Council; NSIP, non-specific interstitial pneumonia.

---

of 93 patients had lung cancer in contrast to the number reported in a previous study. Our institution is a teaching and community hospital, and the patient population may be different from that of a university hospital.

The pulmonary function indices of the CPFE patients included in the present study were rather different from those in previous reports. The CPFE patients in those studies had greater preserved lung volume despite reduced DLco, reduced transfer coefficient for carbon monoxide ($K_{co}$) and hypoxaemia. Jankowich and Rounds reported that CPFE altered physiology but had a mortality rate similar to that of IPF. In addition, Peng et al. reported similar physiology results for CPFE. In our study, the mean per cent predicted FVC was 63.86% and that of FEV1 was 70.95%, which showed more restrictive impairment compared with previous cases. This finding can be explained by the greater volume loss of the lower lung field due to severe fibrosis rather than by the offset effect of emphysema. This finding might also be because our cohort had less emphysema area compared with the previously reported cases. Another possibility is that the patients might have been in a different phase of CPFE. Recently, Rogliani et al. reported the pathology of IPF and emphysema. They evaluated 17 biopsy-proven UIP patients and found fibroblasts in areas of parenchymal destruction from emphysema/UIP-expressed matrix metalloproteinase (MMP)-2, MMP-9, MMP-7 and membrane type 1 (MT1)—MMP at significantly higher levels when compared with emphysema subjects. On the basis of this result, similar to the findings of the study by Rogliani et al. cited above, interstitial fibroblast activation could be stimulated to a greater degree in the areas of lung destruction in CPFE compared with emphysema alone, as in exaggerated tissue remodelling. Therefore, some of the CPFE patients may have had more intense fibrosis, which contributed to reduced FVC.

In the analysis of the HRCT images, the patients were divided into two groups by UIP pattern and NSIP pattern according to the ATS/ERS criteria. All the UIP-pattern patients had honeycombing, and the NSIP-pattern patients more often had consolidation (60% vs 29%) and ground-glass opacity (100% vs 34%). These findings were very similar to those from a recent report on HRCT for NSIP. Sumikawa et al. reported that traction bronchiectasis and fibrosis scores

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Predictor of acute exacerbation in CPFE patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>Age</td>
<td>0.9691 (0.8985 to 1.0453)</td>
</tr>
<tr>
<td>mMRC</td>
<td>0.6681 (0.3538 to 1.2616)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>0.8967 (0.8169 to 0.9844)</td>
</tr>
<tr>
<td>Duration</td>
<td>1.0016 (1.0003 to 1.0027)</td>
</tr>
<tr>
<td>Baseline KL-6</td>
<td>0.7612 (0.2247 to 2.5779)</td>
</tr>
</tbody>
</table>

Table 3: HRCT imaging in CPFE patients

<table>
<thead>
<tr>
<th></th>
<th>UIP pattern (n=68)</th>
<th>NSIP pattern (n=25)</th>
<th>All (n=93)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emphysema pattern</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraseptal, %</td>
<td>57</td>
<td>48</td>
<td>55</td>
</tr>
<tr>
<td>Centrilobular, %</td>
<td>29</td>
<td>32</td>
<td>30</td>
</tr>
<tr>
<td>Panlobular, %</td>
<td>14</td>
<td>20</td>
<td>15</td>
</tr>
<tr>
<td>Fibrosis pattern</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traction bronchiectasis, %</td>
<td>96</td>
<td>88</td>
<td>94</td>
</tr>
<tr>
<td>Reticulation, %</td>
<td>91</td>
<td>88</td>
<td>90</td>
</tr>
<tr>
<td>Honeycombing, %</td>
<td>100</td>
<td>0</td>
<td>73</td>
</tr>
<tr>
<td>Ground-glass opacity, %</td>
<td>34</td>
<td>100</td>
<td>52</td>
</tr>
<tr>
<td>Consolidation, %</td>
<td>29</td>
<td>60</td>
<td>38</td>
</tr>
</tbody>
</table>

Figure 2: Survival curve in CPFE patients.

Figure 3: CPFE patients with clubbing show poor survival compared with that of without clubbing.

were associated with poor prognosis in pathological UIP patients. In the present study, HRCT pattern was not an independent prognostic predictor: CPFE patients usually have more severe PAH, low cardiac index, and are disabled, which we observed in our cohort. Thus, most CPFE patients cannot tolerate invasive procedures such as video-assisted thoracic surgery. Therefore, we cannot compare biopsy-proven UIP with CPFE equally.

AE is a relentlessly progressive status and is associated with poor outcome. Thus, we evaluated AE of CPFE. During the observation period (mean: 30.7 months), 22 patients (24%) developed AE. The annual incidence of AE is 9.4%. This finding is similar to that reported in IPF patients (24%). The annual incidence of AE-IPF is 6%. KL-6 levels in ILD patients reflect the overall impairment compared with that of IPF patients. Another interesting finding was that finger clubbing is related to poor survival in CPFE patients. Finger clubbing usually shows chronicity in ILD patients. However, it predicted clinical course in CPFE patients at our cohort. So, we insist on the importance of initial careful evaluation of physical findings in CPFE.

This time, we did not evaluate the treatment in CPFE patients. Currently, there is no consensus on treatment of CPFE with PAH. This is a vital topic for future study.

There were several limitations in our study. First, this was a single-centre, uncontrolled design retrospective study, which means that it is possible that important data were not collected. Second, we did not measure the exact areas of emphysema and fibrosis. Therefore, our cohort may have been at a different stage compared with previous CPFE patients. Third, most of our patients could not undergo surgical biopsy because of disability and reduced lung function. Thus, we could not evaluate the detailed pathology of our CPFE patients. Fourth, we did not evaluate serial pulmonary function. Recently, Bois et al reported that per cent predicted FVC and the 24 week change in FVC were useful predictors of mortality in IPF. Therefore, it might be helpful to measure serial FVC as a prognostic predictor in CPFE. Lastly, in keeping with previous reports, our study patients were all heavy smokers. Therefore, we could not distinguish CPFE from smoking-related NSIP. However, even considering these limitations, prediction of prognosis using minimally invasive methods in these patients may be quite useful.

In conclusion, CPFE patients showed poor survival in our cohort. CPFE patients often develop AE, for which baseline serum KL-6 was a useful predictor. Finger clubbing and %FEV1/%FVC more than 1.2 were independent prognostic predictors of mortality in patients with CPFE. A multicenter study of this new entity is warranted for further research.

**Table 4** Results of the Cox proportional hazards regression analysis of mortality in CPFE patients

<table>
<thead>
<tr>
<th>HR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finger clubbing</td>
<td>2.2620 (1.1746 to 4.3560)</td>
</tr>
<tr>
<td>%FEV1/</td>
<td>1.9259 (1.0057 to 3.6883)</td>
</tr>
<tr>
<td>%FVC</td>
<td></td>
</tr>
<tr>
<td>CPFE</td>
<td>combined pulmonary fibrosis and emphysema; %FEV1, per cent predicted forced expired volume in one second; FVC, forced vital capacity; %FVC, per cent predicted forced vital capacity.</td>
</tr>
</tbody>
</table>

**Acknowledgements** We would like to thank all residents for their time and efforts with the collection of medical records at Okinawa Chubu Hospital. In addition, we thank Dr Yasutani for interpretation of radiological findings.

**Contributors** TK, YS, HF, KY, MT, SY and HT have substantial contribution to study conception and design, acquisition of data or analysis and interpretation of data. TK, YS, HF, KY, MT, SY and HT have substantial contribution to

---

Mortality predictors in CPFE

drafting the article or revising it critically for important intellectual content. TK, YS, HF, KY, MT, SY and HT have substantial contribution to final approval of the version to be published.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None.

Ethics approval Ethics approval was provided by the Ethics Committee of Okinawa Chubu Hospital.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement There are no additional data available.

REFERENCES

A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema

Tomoo Kishaba, Yousuke Shimaoka, Hajime Fukuyama, Kyoko Yoshida, Maki Tanaka, Shin Yamashiro and Hitoshi Tamaki

BMJ Open 2012 2:
doi: 10.1136/bmjopen-2012-000988

Updated information and services can be found at:
http://bmjopen.bmj.com/content/2/3/e000988

These include:

Supplementary Material
Supplementary material can be found at:
http://bmjopen.bmj.com/content/suppl/2012/05/15/bmjopen-2012-000988.DC1

References
This article cites 35 articles, 6 of which you can access for free at:
http://bmjopen.bmj.com/content/2/3/e000988#BibL

Open Access
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Respiratory medicine (331)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/